Journal
CLINICAL CANCER RESEARCH
Volume 26, Issue 3, Pages 523-525Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-19-3645
Keywords
-
Categories
Ask authors/readers for more resources
Metformin is an affordable and well-tolerated drug used in type 2 diabetes. Potential anticancer effects of metformin in gynecologic malignancies include inhibition of the PI3K-mTOR pathway, hormone receptor regulation, and reduction of fibrosis and inflammation. Multiple studies are currently assessing its role in cancer prevention and as a treatment enhancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
